Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Driven Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,777,426

295 payments

Through program year 2025, Driven Research LLC is reported as receiving $2,777,426 in research payments, across 295 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $1,409,687 140
2024 Research $1,187,062 120
2023 Research $155,252 27
2022 Research $25,425 8

Breakdown

Who paid Research payments · program years 2022–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $918,065 52 payments
  2. Eli Lilly and Company $496,576 14 payments
  3. Janssen Research & Development, LLC $467,310 32 payments
  4. Incyte Corporation $271,493 120 payments
  5. Sanofi US Services Inc. $171,026 11 payments
  6. AbbVie, Inc. $125,154 22 payments
  7. Novartis Pharmaceuticals Corporation $103,284 2 payments
  8. Amgen Inc. $94,137 6 payments
  9. Sun Pharmaceutical Industries Inc. $50,114 9 payments
  10. E.R. Squibb & Sons, L.L.C. $42,526 5 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment $668,689 33 payments
  2. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $282,674 22 payments
  3. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of Ly4100511 (Dc-853) for the Treatment of Adult Participants With Moderate-To Severe Plaque Psoriasis $219,746 2 payments
  4. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $199,168 13 payments
  5. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $179,636 9 payments
  6. A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis $171,026 11 payments
  7. A Study of Ly3972406 in Adult Participants With Moderate-To-Severe Plaque Psoriasis $127,604 4 payments
  8. A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $114,867 18 payments
  9. A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup $103,284 2 payments
  10. A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $90,658 63 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record